HRP20240357T1 - Stanica - Google Patents

Stanica Download PDF

Info

Publication number
HRP20240357T1
HRP20240357T1 HRP20240357TT HRP20240357T HRP20240357T1 HR P20240357 T1 HRP20240357 T1 HR P20240357T1 HR P20240357T T HRP20240357T T HR P20240357TT HR P20240357 T HRP20240357 T HR P20240357T HR P20240357 T1 HRP20240357 T1 HR P20240357T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
car
acid sequence
sequence encoding
domain
Prior art date
Application number
HRP20240357TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin PULÉ
Shaun CORDOBA
Shimobi ONUOHA
Simon Thomas
Original Assignee
Autolus Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20240357(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Autolus Limited filed Critical Autolus Limited
Publication of HRP20240357T1 publication Critical patent/HRP20240357T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
HRP20240357TT 2014-12-24 2015-12-23 Stanica HRP20240357T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201423172 2014-12-24
EP19172397.2A EP3560953B1 (en) 2014-12-24 2015-12-23 Cell

Publications (1)

Publication Number Publication Date
HRP20240357T1 true HRP20240357T1 (hr) 2024-06-07

Family

ID=55066668

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240357TT HRP20240357T1 (hr) 2014-12-24 2015-12-23 Stanica

Country Status (26)

Country Link
US (8) US11091532B2 (enExample)
EP (3) EP3237442B1 (enExample)
JP (5) JP6633081B2 (enExample)
KR (6) KR102376242B1 (enExample)
CN (2) CN114107212A (enExample)
AU (5) AU2015370679C1 (enExample)
BR (1) BR112017013690A2 (enExample)
CA (2) CA3224507A1 (enExample)
CL (3) CL2017001314A1 (enExample)
DK (2) DK3237442T3 (enExample)
ES (2) ES2744910T3 (enExample)
FI (1) FI3560953T3 (enExample)
HR (1) HRP20240357T1 (enExample)
HU (2) HUE066020T2 (enExample)
IL (4) IL301458A (enExample)
LT (1) LT3560953T (enExample)
MX (1) MX2017006233A (enExample)
PL (2) PL3237442T3 (enExample)
PT (2) PT3237442T (enExample)
RS (1) RS65343B1 (enExample)
RU (2) RU2768019C2 (enExample)
SG (2) SG11201704084VA (enExample)
SI (1) SI3560953T1 (enExample)
SM (1) SMT202400134T1 (enExample)
WO (1) WO2016102965A1 (enExample)
ZA (1) ZA201703381B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
KR102376242B1 (ko) 2014-12-24 2022-03-21 오토러스 리미티드 세포
EP4134430A1 (en) 2015-02-06 2023-02-15 National University of Singapore Methods for enhancing efficacy of therapeutic immune cells
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
HK1246317A1 (zh) 2015-03-05 2018-09-07 Fred Hutchinson Cancer Center 免疫调节融合蛋白及其用途
HUE059218T2 (hu) * 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
EP4353750A3 (en) * 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
KR20250072712A (ko) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 합성 면역 수용체 및 이의 사용 방법
JP2020503015A (ja) * 2016-12-13 2020-01-30 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
EP3567049A4 (en) * 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
AU2018251206A1 (en) * 2017-04-14 2019-10-31 The General Hospital Corporation Chimeric antigen receptor T cells targeting the tumor microenvironment
ES2905377T3 (es) * 2017-04-18 2022-04-08 Autolus Ltd Célula
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CA3062433A1 (en) * 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN109385402A (zh) * 2017-08-11 2019-02-26 上海恒润达生生物科技有限公司 一种等比例混合两种靶点cart细胞的制备方法及应用
CN107446937B (zh) * 2017-09-05 2020-12-25 深圳华云生物技术有限公司 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
EP3684408A1 (en) 2017-09-19 2020-07-29 Massachusetts Institute of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
WO2019079249A1 (en) * 2017-10-16 2019-04-25 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN108101994B (zh) * 2018-01-04 2020-09-15 广东万海细胞生物科技有限公司 抗cd19抗体及其应用
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
BR112020015884A2 (pt) 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
JP2021512635A (ja) * 2018-02-12 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的とするキメラ抗原受容体
CN110157738B (zh) * 2018-02-13 2023-06-27 亘喜生物科技（上海）有限公司 靶向cd19和cd22的工程化免疫细胞及其应用
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CA3099831A1 (en) * 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
CA3100386A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
CN112334479A (zh) * 2018-07-13 2021-02-05 南京传奇生物科技有限公司 用于治疗感染性疾病的共受体系统
KR20210066865A (ko) 2018-09-27 2021-06-07 오토러스 리미티드 키메라 항원 수용체
JP7557882B2 (ja) 2018-09-28 2024-09-30 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
GB201820547D0 (en) * 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
JP7602475B2 (ja) * 2019-03-08 2024-12-18 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
SG11202112536UA (en) * 2019-05-16 2021-12-30 Nanjing Legend Biotech Co Ltd Engineered immune cells comprising a recognition molecule
US20200384029A1 (en) * 2019-06-07 2020-12-10 The Trustees Of The University Of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
US20220257757A1 (en) 2019-07-16 2022-08-18 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
JP2022543658A (ja) 2019-08-07 2022-10-13 アクアラン セラピューティクス コーポレーション 抗ｎａｍｐｔ抗体及びその用途
CN112390891B (zh) * 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
CN110903401A (zh) * 2019-11-20 2020-03-24 浙江大学 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用
AU2020393912B2 (en) * 2019-11-26 2025-11-20 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
PH12022551290A1 (en) 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
JP7744914B2 (ja) * 2020-02-04 2025-09-26 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート ハプテン標識細胞によりキメラ抗原受容体ｔ細胞を刺激する方法およびそのための組成物
CN115843255A (zh) * 2020-03-11 2023-03-24 约瑟夫卡雷拉斯白血病研究基金会 用于治疗b细胞型急性淋巴细胞白血病（b-all）的cd22靶向部分
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
IL298909A (en) 2020-06-17 2023-02-01 Janssen Biotech Inc Materials and methods for the manufacture of pluripotent stem cells
IL300001A (en) 2020-07-24 2023-03-01 Massachusetts Gen Hospital Enhanced virus-like particles and methods of use thereof for delivery to cells
EP4203981A2 (en) * 2020-08-25 2023-07-05 CytoImmune Therapeutics, Inc. Bispecific antibody car cell immunotherapy
JP2023553419A (ja) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド 遺伝子操作細胞およびその使用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN112481284B (zh) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR102393776B1 (ko) 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
WO2023016554A1 (zh) * 2021-08-13 2023-02-16 上海医药集团股份有限公司 靶向cd22的抗原结合蛋白及其用途
KR102829757B1 (ko) * 2021-11-17 2025-07-09 (주)이노베이션바이오 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
WO2023218381A1 (en) 2022-05-11 2023-11-16 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
JP2025525612A (ja) 2022-07-22 2025-08-05 ヤンセン バイオテツク，インコーポレーテツド エフェクター免疫細胞への遺伝的命令の増強された移入
US20240197780A1 (en) * 2022-12-19 2024-06-20 Development Center For Biotechnology Chimeric antigen receptors, nucleic acids encoding the same, and uses thereof in treating cancers
AU2024240255A1 (en) * 2023-03-17 2025-10-02 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2024246526A1 (en) 2023-05-30 2024-12-05 Autolus Limited Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
WO2024250037A1 (en) * 2023-06-02 2024-12-05 Northeastern University Targeted immune cell therapy utilizing trail and tnf mediated apoptosis
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299011A1 (fr) 1975-01-29 1976-08-27 Obert Jean Claude Generateur d'aerosols de part
WO2000063374A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic transmembrane components
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
ATE338124T1 (de) * 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
JP2008501621A (ja) * 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
ES2532124T3 (es) 2005-12-16 2015-03-24 Amgen Research (Munich) Gmbh Medios y procedimientos para el tratamiento de enfermedades tumorales
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2768863B1 (en) 2011-10-20 2017-09-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd22 chimeric antigen receptors
US9447194B2 (en) * 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
ES2786263T3 (es) 2012-07-13 2020-10-09 Univ Pennsylvania Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
MX370148B (es) * 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2013335180B2 (en) * 2012-10-24 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
AU2014214850C1 (en) * 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
ES2671004T3 (es) 2013-03-07 2018-06-04 Baylor College Of Medicine Dirección a CD138 en cáncer
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP4098275A1 (en) 2013-03-15 2022-12-07 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
MX374681B (es) 2013-05-13 2025-03-06 Cellectis Receptor quimérico de antígeno específico para cd19 y sus usos.
EP3021853A1 (en) 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
RU2717984C2 (ru) 2013-11-21 2020-03-27 ЮСиЭл БИЗНЕС ЛТД Клетка
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
KR102376242B1 (ko) 2014-12-24 2022-03-21 오토러스 리미티드 세포
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell
CA3099831A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor

Also Published As

Publication number Publication date
ES2744910T3 (es) 2020-02-26
JP2024055976A (ja) 2024-04-19
KR20220129684A (ko) 2022-09-23
US20250353893A1 (en) 2025-11-20
LT3560953T (lt) 2024-05-10
CN107002045A (zh) 2017-08-01
EP4368704A2 (en) 2024-05-15
KR20210098557A (ko) 2021-08-10
WO2016102965A1 (en) 2016-06-30
CL2018003216A1 (es) 2019-02-01
AU2015370679C1 (en) 2020-09-10
IL274903A (en) 2020-07-30
HUE066020T2 (hu) 2024-07-28
DK3237442T3 (da) 2019-09-23
HUE046262T2 (hu) 2020-02-28
SI3560953T1 (sl) 2024-05-31
CL2017001314A1 (es) 2017-12-15
US11091532B2 (en) 2021-08-17
US10174099B2 (en) 2019-01-08
AU2024278248A1 (en) 2025-01-30
MX2017006233A (es) 2017-10-24
KR20210098556A (ko) 2021-08-10
AU2020213352A1 (en) 2020-08-27
DK3560953T5 (da) 2024-09-02
US11034750B2 (en) 2021-06-15
DK3560953T3 (da) 2024-04-02
PL3237442T3 (pl) 2020-02-28
JP7514746B2 (ja) 2024-07-11
KR102376242B1 (ko) 2022-03-21
EP3560953B1 (en) 2024-01-31
EP3237442A1 (en) 2017-11-01
CA2970440A1 (en) 2016-06-30
AU2022205169B2 (en) 2024-09-26
KR20230152824A (ko) 2023-11-03
AU2022205169A1 (en) 2022-09-15
US12398194B2 (en) 2025-08-26
US20170369550A1 (en) 2017-12-28
RS65343B1 (sr) 2024-04-30
US20170340705A1 (en) 2017-11-30
CA3224507A1 (en) 2016-06-30
CL2018003217A1 (es) 2019-02-01
RU2017121892A3 (enExample) 2019-05-28
US10098926B2 (en) 2018-10-16
KR102085349B1 (ko) 2020-03-06
AU2015370679B2 (en) 2020-05-21
BR112017013690A2 (pt) 2018-03-06
EP3560953A1 (en) 2019-10-30
EP3237442B1 (en) 2019-07-10
US20200181232A1 (en) 2020-06-11
KR20200003939A (ko) 2020-01-10
NZ731778A (en) 2024-02-23
ES2976197T3 (es) 2024-07-26
KR20170092695A (ko) 2017-08-11
JP2021036913A (ja) 2021-03-11
KR102376244B1 (ko) 2022-03-21
US20180371054A1 (en) 2018-12-27
IL252208A0 (en) 2017-07-31
AU2020213352B2 (en) 2022-08-18
FI3560953T3 (fi) 2024-03-21
CN107002045B (zh) 2025-10-21
IL292508B2 (en) 2023-08-01
SMT202400134T1 (it) 2024-05-14
RU2017121892A (ru) 2019-01-24
PT3237442T (pt) 2019-09-26
US10981970B2 (en) 2021-04-20
AU2015370679A1 (en) 2017-06-01
US20170340704A1 (en) 2017-11-30
IL301458A (en) 2023-05-01
IL252208B (en) 2021-10-31
RU2022102250A (ru) 2022-03-23
IL292508A (en) 2022-06-01
JP6909844B2 (ja) 2021-07-28
CN114107212A (zh) 2022-03-01
SG10202111107RA (en) 2021-11-29
JP2022002546A (ja) 2022-01-11
SG11201704084VA (en) 2017-06-29
ZA201703381B (en) 2018-08-29
RU2768019C2 (ru) 2022-03-23
IL274903B (en) 2022-07-01
JP6633081B2 (ja) 2020-01-22
PL3560953T3 (pl) 2024-05-13
JP2018501794A (ja) 2018-01-25
AU2022205170B2 (en) 2025-02-27
AU2022205170A1 (en) 2022-09-15
IL292508B1 (en) 2023-04-01
PT3560953T (pt) 2024-03-26
JP2020022508A (ja) 2020-02-13
US20230331810A1 (en) 2023-10-19
EP4368704A3 (en) 2024-05-29
US20190161531A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
HRP20240357T1 (hr) Stanica
HRP20202024T1 (hr) Cd3-vežuća domena
HRP20240767T1 (hr) Cd3 vezujuća antitijela
WO2017172981A3 (en) Chimeric antigen receptors targeting cancer
IL292650B2 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
RU2017125531A (ru) Химерные антигенные рецепторы и способы их применения
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
HRP20191704T1 (hr) Multispecifična protutijela
HRP20220799T1 (hr) Klaudin-18-2-specifični imunoreceptori i stanični epitopi t
RU2017105515A (ru) Сигнальная система
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP2018504894A5 (enExample)
WO2010070145A3 (en) Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
MX367787B (es) Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
JP2014534207A5 (enExample)
MY198560A (en) Bispecific antibodies specific for a costimulatory tnf receptor
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
HRP20211978T1 (hr) Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe
IL269270B (en) Method and preparations for cellular immunotherapy
HK1243333A1 (zh) 用於修饰的t细胞的方法和组合物
JP2019527537A5 (enExample)
RU2016138422A (ru) Химерный антигенный рецептор
WO2013041844A3 (en) Antibodies, variable domains & chains tailored for human use